Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15635878 | 0.87 | OPRK1 (0.48) | OPRK1ALDH1A1HSD17B10NPC1MAPT | |
| SCHEMBL29856041 | 0.84 | OPRK1 (0.48) | OPRK1 | |
| SCHEMBL3344339 | 0.84 | OPRK1 (0.48) | OPRK1 | |
| SCHEMBL3580016 | 0.84 | KDM4E (0.49) | ALDH1A1HSD17B10NPC1MAPTKDM4E | |
| SCHEMBL24002823 | 0.82 | TSHR (0.46) | OPRK1ALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL2436257 | 0.82 | KDM4E (0.48) | ALDH1A1HSD17B10NPC1MAPTKDM4E | |
| SCHEMBL9251545 | 0.82 | MAPT (0.48) | OPRK1ALDH1A1HSD17B10NPC1MAPT | |
| SCHEMBL5864153 | 0.81 | OPRK1 (0.50) | OPRK1ALDH1A1HSD17B10NPC1MAPT | |
| SCHEMBL15527494 | 0.81 | OPRK1 (0.50) | OPRK1ALDH1A1HSD17B10NPC1MAPT | |
| SCHEMBL10580383 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HSD17B10NPC1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-06 | — | — | US | disclosed |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-03 | — | — | US | disclosed |
| US-20220315580-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3580220-B1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| CN-110520423-A | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO | 2019-11-29 | — | — | CN | disclosed |
| WO-2018148626-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-16 | — | — | WO | disclosed |
| EP-1984340-B1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1984340-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2007090752-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | OPRK1 607/4885ALDH1A1 4186/4885HSD17B10 4470/4885 |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | OPRK1 673/4885ALDH1A1 1414/4885HSD17B10 2275/4885 |
| US-20220315580-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | OPRK1 607/4885ALDH1A1 4186/4885HSD17B10 4470/4885 |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | OPRK1 607/4885ALDH1A1 4186/4885HSD17B10 4470/4885 |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | OPRK1 470/4885ALDH1A1 4194/4885HSD17B10 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.